Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against the other stocks that received a downgrade from Wall Street analysts. But first, we are going to take a look at what the markets are doing. Amidst the anticipation surrounding pivotal economic indicators, European futures are on the ascent, signaling a cautious optimism among traders as they prepare for the release of crucial US inflation figures and the Federal Reserve's forthcoming monetary-policy decision. While Asian equities faced a downturn, European stock futures, particularly contracts on the Euro Stoxx 50 Index, exhibited a marginal uptick of 0.2%. Concurrently, treasuries in Asia recorded marginal gains, while Bloomberg's dollar index extended its streak of consecutive advancements. With Wednesday's release of the US Consumer Price Index (CPI) data and the Fed's policy announcement looming, analysts remain vigilant, mindful of the potential resurgence in market volatility. Despite the backdrop of market uncer
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Benchmark Co. from $50.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple SclerosisPR Newswire
- Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 5/7/24 - Beat
HALO
Sec Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 144
- 6/14/24 - Form 4
- HALO's page on the SEC website